Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Argus Health
McKesson
AstraZeneca
Chinese Patent Office
Johnson and Johnson
Chubb
Covington
Federal Trade Commission
US Army

Generated: August 18, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,208,489 protect, and when does it expire?


Patent ► Subscribe protects IBRANCE and is included in one NDA.

This patent has sixty-four patent family members in forty-six countries.

Summary for Patent: ► Subscribe

Title:2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4) ##STR00001##
Inventor(s): Barvian; Mark (Ann Arbor, MI), Booth; Richard John (Ann Arbor, MI), Quin, III; John (Ann Arbor, MI), Repine; Joseph Thomas (Ann Arbor, MI), Sheehan; Derek J. (Dexter, MI), Toogood; Peter Laurence (Ann Arbor, MI), Vanderwel; Scott Norman (Ann Arbor, MI), Zhou; Hairong (Ann Arbor, MI)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:11/046,126
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-001Feb 3, 2015RXYesNo► Subscribe► SubscribeYY
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-002Feb 3, 2015RXYesNo► Subscribe► SubscribeYY
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-003Feb 3, 2015RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,936,612 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones► Subscribe
7,456,1682-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland372046► Subscribe
Peru09752003► Subscribe
Panama8563701► Subscribe
African Intellectual Property Organization (OAPI)12755► Subscribe
New Zealand534069► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Colorcon
Accenture
Citi
Teva
Novartis
Baxter
Cantor Fitzgerald
Fish and Richardson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot